Centene (CNC) Q2 2026 earnings review
The Turnaround is Real, but Aided by One-Timers
Centene's brutal 2025 is officially in the rearview mirror. The aggressive medicine management prescribed a year ago—drastically repricing the Marketplace book and shedding unprofitable membership—has worked. Q2 2026 Adjusted EPS came in at $2.51, completely reversing the $0.16 loss from a year ago. The Commercial Health Benefits Ratio (HBR) collapsed to 79.2% from 90.6%, driving massive profitability improvements despite intentional volume destruction. Consequently, management raised the FY26 Adjusted EPS floor substantially from >$3.40 to >$4.80. However, investors should temper their excitement slightly: ~$0.50 of this guidance raise stems from non-recurring programmatic resolutions, artificially inflating the 'underlying strength' narrative.
🐂 Bull Case
The massive repricing strategy executed for the 2026 plan year was a resounding success. Commercial HBR improved by 1,140 basis points YoY to 79.2%, validating management's ability to correct underwriting mistakes.
Total revenue guidance was increased by $6.0 billion, and the Adjusted EPS floor was raised by $1.40. The core business engine is generating significantly more cash and profit than previously modeled.
🐻 Bear Case
Management explicitly noted that approximately $0.50 of the EPS guidance increase is driven by non-recurring items in Medicare and Commercial. The true run-rate of the business is lower than the headline >$4.80 suggests.
Marketplace membership plummeted by 40% YoY (5.86M to 3.49M). While this was a deliberate move to prioritize margin over volume, returning to sustainable top-line growth without sacrificing this newfound profitability remains untested.
⚖️ Verdict: 🟢
Bullish. Management promised a margin recovery, and they delivered exactly that. While the non-recurring items flatter the guidance raise, the structural fix to the Commercial risk pool is a massive win.
Key Themes
Marketplace Repricing Triumphs
A year ago, Centene suffered a $2.4 billion pre-tax headwind due to mispricing Marketplace morbidity. Today, the turnaround is complete. By aggressively raising rates (averaging mid-30s percentage increases for 2026), the Commercial segment HBR reversed violently from 90.6% in 25Q2 to 79.2% in 26Q2. This margin expansion easily offset the 7% decline in Commercial premium revenue.
Medicare PDP as the Growth Engine
While Commercial and Medicaid membership shrank, the Medicare segment is accelerating. Total Medicare revenue grew 17% YoY to $11.05 billion. This was primarily driven by strong enrollment growth in the Prescription Drug Plan (PDP) business, which added nearly 1 million members YoY (reaching 8.8 million). PDP also operates at a significantly lower SG&A ratio, aiding consolidated margins.
Data Contradiction: 'Underlying Strength' vs. One-Timers
Management attributed the guidance raise to 'underlying strength,' yet explicitly stated the raise includes ~$0.50 of non-recurring items in the Medicare and Commercial segments. Additionally, 26Q2 results benefited from a favorable 2025 programmatic resolution and the lack of a Premium Deficiency Reserve (PDR) versus 2025. These accounting items flatter the YoY comparables and inflate the structural earnings power narrative.
Intentional Volume Destruction
To save margins, Centene had to torch its membership base. Total at-risk membership is down from 28.0 million to 25.8 million YoY. The Marketplace (down 2.3M members) and Medicaid (down 0.7M members) segments are structurally smaller. The market will eventually demand a pivot back to top-line growth, which carries renewed risk of mispricing.
Medicaid Redeterminations Stable, but Pricing Matters
Medicaid membership fell by roughly 700k YoY due to ongoing redeterminations. However, segment revenue still grew 5% to $22.7 billion. This indicates that state rate increases and higher acuity premiums are successfully offsetting volume losses. The HBR remained relatively stable at 93.9% (vs 94.9% YoY), indicating that cost trends are finally being matched by rate adequacy.
SG&A Operating Leverage
Despite a massive drop in higher-revenue Commercial members, Centene improved its Adjusted SG&A ratio from 7.1% to 6.9%. Management achieved this through strict cost discipline, the wind-down of legacy contracts, and the mix shift toward the hyper-efficient PDP segment.
Other KPIs
Accelerating significantly. H1 2026 Operating Cash Flow reached nearly $8.0 billion (compared to $3.3 billion in H1 2025). This massive cash generation is allowing the company to aggressively pay down debt, repurchasing $260 million of 2027/2028 senior notes during the quarter.
Stable. DCP decreased by one day sequentially from Q1 2026, driven strictly by the timing of state-directed payments. Medical claims liabilities total $20.3 billion, showing no signs of aggressive reserve releases to pad earnings.
Guidance
Accelerating aggressively. Raised from the previous floor of >$3.40 given in Q1. While $0.50 of this is tied to non-recurring items, this still represents a >130% recovery from the depressed 2025 level of $2.08.
Accelerating. Raised by $6.0 billion from the prior outlook, primarily driven by higher premium tax revenue, Medicaid rate increases, and strong Marketplace yield per member.
Improving (Lower is better). The midpoint of 90.9% indicates a tightening of medical cost controls across the enterprise, largely anchored by the successful repricing of the Commercial segment.
Key Questions
Visibility into Non-Recurring Benefits
You noted ~$0.50 of the EPS guidance increase is tied to non-recurring items in Medicare and Commercial. Could you break down exactly what these programmatic elements were, and confirm whether the $4.30 implied core run-rate is the right baseline for 2027?
Pivot to Growth in Marketplace
With the Commercial HBR now running at an exceptional 79.2%, you have clearly fixed the margin profile. When and how do you plan to pivot back toward membership growth in the Marketplace, given the 40% YoY volume drop?
Medicaid Acuity Trends
Medicaid HBR stabilized at 93.9%. As redeterminations near their final tail, are you seeing any lingering shifts in the morbidity pool, or have state rate adjustments completely caught up to underlying trend?